Halozyme Therapeutics (NASDAQ:HALO) Hits New 52-Week High – Here’s What Happened

Halozyme Therapeutics, Inc. (NASDAQ:HALO) shares reached a new 52-week high on Friday . The company traded as high as $82.99 and last traded at $81.5140, with a volume of 217609 shares trading hands. The stock had previously closed at $80.84.

Analyst Ratings Changes

HALO has been the topic of several analyst reports. Wall Street Zen raised shares of Halozyme Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, May 16th. Benchmark reissued a “buy” rating on shares of Halozyme Therapeutics in a research report on Tuesday. HC Wainwright restated a “buy” rating and set a $95.00 target price on shares of Halozyme Therapeutics in a research note on Tuesday, July 21st. Weiss Ratings raised Halozyme Therapeutics from a “hold (c)” rating to a “buy (b-)” rating in a research report on Tuesday, May 12th. Finally, Morgan Stanley cut their price target on Halozyme Therapeutics from $96.00 to $93.00 and set an “overweight” rating on the stock in a research note on Tuesday, May 12th. Eight investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $81.60.

Halozyme Therapeutics Price Performance

The company has a debt-to-equity ratio of 8.81, a current ratio of 2.76 and a quick ratio of 2.33. The business’s 50-day moving average price is $73.08 and its two-hundred day moving average price is $70.58. The firm has a market cap of $9.72 billion, a price-to-earnings ratio of 29.47, a P/E/G ratio of 0.34 and a beta of 0.84.

Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings results on Monday, May 11th. The biopharmaceutical company reported $1.60 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.54 by $0.06. Halozyme Therapeutics had a net margin of 23.13% and a return on equity of 187.91%. The firm had revenue of $376.71 million for the quarter, compared to analysts’ expectations of $358.60 million. During the same period in the prior year, the company posted $1.11 earnings per share. The firm’s quarterly revenue was up 42.2% on a year-over-year basis. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS. On average, research analysts forecast that Halozyme Therapeutics, Inc. will post 7.54 EPS for the current fiscal year.

Insider Transactions at Halozyme Therapeutics

In related news, CEO Helen Torley sold 1,923 shares of Halozyme Therapeutics stock in a transaction dated Wednesday, July 8th. The stock was sold at an average price of $79.77, for a total value of $153,397.71. Following the completion of the transaction, the chief executive officer directly owned 767,780 shares in the company, valued at approximately $61,245,810.60. This trade represents a 0.25% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mahesh Krishnan sold 7,304 shares of Halozyme Therapeutics stock in a transaction dated Monday, June 29th. The stock was sold at an average price of $75.00, for a total value of $547,800.00. Following the completion of the transaction, the director owned 14,462 shares of the company’s stock, valued at $1,084,650. This trade represents a 33.56% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 74,102 shares of company stock valued at $5,205,798. Insiders own 2.50% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of HALO. Larson Financial Group LLC increased its holdings in shares of Halozyme Therapeutics by 3,118.2% in the 3rd quarter. Larson Financial Group LLC now owns 354 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 343 shares during the last quarter. Measured Wealth Private Client Group LLC raised its position in shares of Halozyme Therapeutics by 51.5% during the 4th quarter. Measured Wealth Private Client Group LLC now owns 365 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 124 shares in the last quarter. Harbour Investments Inc. lifted its stake in Halozyme Therapeutics by 152.5% during the fourth quarter. Harbour Investments Inc. now owns 616 shares of the biopharmaceutical company’s stock worth $41,000 after purchasing an additional 372 shares during the last quarter. Clearstead Advisors LLC lifted its stake in Halozyme Therapeutics by 64.8% during the fourth quarter. Clearstead Advisors LLC now owns 842 shares of the biopharmaceutical company’s stock worth $57,000 after purchasing an additional 331 shares during the last quarter. Finally, Wexford Capital LP bought a new position in Halozyme Therapeutics during the third quarter worth $70,000. Institutional investors own 97.79% of the company’s stock.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.